Get the Stockscreener App
5.99
2.92%
-0.18
After Hours:
5.73
-0.26
-4.34%
Nextcure Inc stock is traded at $5.99, with a volume of 803.29K.
It is down -2.92% in the last 24 hours and up +172.27% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
See More
Previous Close:
$6.17
Open:
$6.05
24h Volume:
803.29K
Relative Volume:
0.42
Market Cap:
$24.37M
Revenue:
-
Net Income/Loss:
$-54.66M
P/E Ratio:
-0.3141
EPS:
-19.0729
Net Cash Flow:
$-49.98M
1W Performance:
+204.06%
1M Performance:
+172.27%
6M Performance:
-53.60%
1Y Performance:
+16.76%
1-Day Range:
$5.6801
$6.50
1-Week Range:
$1.70
$9.90
52-Week Range:
$1.55
$15.74
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.99 | 25.11M | 0 | -54.66M | -49.98M | -19.07 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure and Avere Therapeutics Announce Merger and $320 Million Private Financing - Global Legal Chronicle
NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan - Stock Titan
NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny - StocksToTrade
H.C. Wainwright reiterates NextCure stock rating on merger news - Investing.com
H.C. Wainwright reiterates NextCure stock rating on merger news By Investing.com - Investing.com UK
Beltsville's NextCure merging with San Francisco startup - The Business Journals
Dow Falls Over 100 Points Following Inflation Data; Crude Oil Gains - Sahm
NextCure Announces Transformative All-Stock Merger With Avere - TipRanks
NextCure, Avere Therapeutics enter definitive merger agreement - TipRanks
Law firm investigates if NextCure shareholders get a fair price in merger with Avere Therapeutics. - Pluang
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - GlobeNewswire Inc.
Avere, NextCure Merge To Take AVR-001 Ahead In Psoriasis, Ulcerative Colitis - insights.citeline.com
After $5 billion-plus Novo Nordisk buyout, this biotech band is playing an encore with big merger plans - The Business Journals
Power Moves: NXTC, TOON, SHPH, COCH Entry Points Ignite on Major Catalysts - FinancialContent
Why Did NextCure Stock 3X In One Session?NextCure (NASDAQ:NXTC) - Benzinga
Law firm investigates NextCure merger fairness as shareholders get 1.21% stake in combined company - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC) - PR Newswire
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
NextCure, Inc. (NXTC) Stock: Soars 218% After Avere Merger and $320M Private Placement Deal - parameter.io
NextCure Inc. (NXTC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NextCure stock surge puts cash payout and 1.21% Avere stake under the lens - TechStock²
NextCure faces investigation over merger terms with Avere Therapeutics amid shareholder concerns. - Pluang
NextCure and Avere Therapeutics Announce $320M Merger to Advance Once-Weekly Oral IL-23 Therapy for Psoriasis and Ulcerative Colitis 12 – Minichart - Minichart
Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders - PR Newswire
NXTC Stock Alert: Halper Sadeh LLC is Investigating Whether NextCure, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan - Quiver Quantitative
NextCure backs Avere merger with $320 million financing - grafa.com
Avery Therapeutics, Inc. entered into a definitive merger agreement to acquire NextCure, Inc. for $250 million in a reverse merger transaction. - marketscreener.com
NXTC Stock Rockets On Massive Volume As Traders Pile In - StocksToTrade
NextCure to merge with Avere Therapeutics in $320M deal By Investing.com - Investing.com Australia
NextCure (NXTC) Stock Skyrockets 300% Following $320M Avere Therapeutics Merger Agreement - parameter.io
NextCure (NXTC) Stock Rockets 300% Following $320M Avere Therapeutics Merger Announcement - MoneyCheck
NextCure (NXTC) Stock Skyrockets 300% Following $320 Million Avere Therapeutics Merger Agreement - Blockonomi
NextCure (NXTC) Stock Surges 300% on $320M Merger Deal With Avere Therapeutics - CoinCentral
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
NextCure and Avere Therapeutics Merge, Raise $320 Million to Advance Oral IL-23 Program - citybiz
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill - Yahoo Finance
NextCure to merge with privately-held Avere (NXTC:NASDAQ) - Seeking Alpha
NextCure (NASDAQ: NXTC) plans reverse merger; Avere holders to own about 98% - Stock Titan
NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company - TradingView
NextCure (NASDAQ: NXTC) sets Avere merger backed by $320M raise - Stock Titan
NextCure to merge with Avere Therapeutics in $320M deal - Investing.com
NextCure and Avere Therapeutics Announce Definitive Merger and $320 Million Financing to Advance Oral IL-23 Therapy AVR-001 - Quiver Quantitative
NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy - The Manila Times
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug - Endpoints News
What's going on with NextCure stock Wednesday? - MSN
Price to sales forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Price to sales forward of NextCure, Inc. – LSX:A41AKJ - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – NASDAQ:NXTC - TradingView
Enterprise value to EBITDA forward of NextCure, Inc. – MUN:2US0 - TradingView
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):